

Neuropazine

A drug created and manufactured by [Advancer Enterprises](#), it entered Advancer's [pharmaceutical catalog](#) in late [YE 45](#). Neuropazine is a specialized neurological medication designed to improve nerve conduction and overall nervous system function.

»Optional Image«	
Year Created:	YE 45
Designer / Manufacturer:	Advancer Enterprises
Nomenclature:	AE-N14
Price:	25 KS per 100mg/10ml vial
Drug Class	neuroregenerative

History

Neuropazine was conceived in early [YE 45](#) as part of Advancer Enterprises' broader initiative to tackle neurological disorders. The project was spearheaded by Dr. Lena Quill, a neuroscientist with a specialized focus on neuropharmacology. Dr. Quill and her team were driven by the need to address the limitations of existing treatments for neurological conditions. They aimed to create a medication that could not only alleviate symptoms but also restore damaged neural pathways, offering a more holistic approach to treatment.

The drug underwent a rigorous series of pre-clinical trials, including in vitro and in vivo studies, to evaluate its efficacy and safety profile. The results were promising, showing significant improvements in nerve conduction and synaptic transmission. This led to fast-tracking the drug for human clinical trials, which further confirmed its therapeutic benefits. By late [YE 45](#), Neuropazine was approved for mass production and was added to Advancer's pharmaceutical catalog.

Usage

Neuropazine is designed to enhance the health and function of nerve cells, also known as neurons. It works by promoting the production and maintenance of the myelin sheath, a protective layer surrounding nerve fibers. This results in optimized signal transmission across synapses, the junctions between neurons. The standard dosage is 100mg, administered intravenously, with each 10ml vial containing a concentration of 10mg/ml.

The drug is particularly effective in managing conditions characterized by nerve damage or dysfunction, such as neuropathy, multiple sclerosis, and certain forms of dementia. It has also shown promise in treating nerve pain conditions like trigeminal neuralgia and diabetic neuropathy. Due to its targeted action, Neuropazine can be a cornerstone in personalized treatment plans for patients suffering from a range of neurological disorders.

Side Effects

Neuropazine is generally well-tolerated, but it is not without potential side effects. Common adverse reactions include mild gastrointestinal upset, dizziness, and occasional fatigue. In rare instances, the drug can induce allergic reactions, manifesting as skin rash, itching, or swelling. Due to its potent effects on the nervous system, Neuropazine should be used cautiously in individuals with pre-existing neurological conditions or those concurrently taking other neurological medications. Regular monitoring by a healthcare professional is strongly advised to assess the drug's impact and adjust treatment protocols accordingly.

Overdose


Overdosing on Neuropazine poses a serious risk of nervous system hyperactivity, which can manifest as seizures or tremors. The overdose threshold is approximately 250mg, twice the standard dosage. Immediate medical intervention is crucial, typically involving the administration of anticonvulsant medications and supportive care to mitigate the effects of the overdose.

OOO Notes

[Demibear](#) created this article on 2023/10/09 23:37.

Approval Thread:
<https://stararmy.com/roleplay-forum/threads/advancer-enterprises-white-lion-type-45-vehicle-aid-kit.71051/>

Star Army Logistics	
Supply Classification	Class J - MEDICAL BIOLOGICAL
Drugs, Medicines, and Pharmaceuticals	
Drug Name(s)	Neuropazine
Route of Administration	intravenous (IV)
Products & Items Database	
Product Categories	drugs
Product Name	Neuropazine
Nomenclature	AE-N14
Manufacturer	Advancer Enterprises
Year Released	YE 45
Price (KS)	25.00 KS



From:

<https://wiki.stararmy.com/> - **STAR ARMY**

Permanent link:

<https://wiki.stararmy.com/doku.php?id=items:drugs:neuropazine>

Last update: **2024/03/13 04:41**

